SynthesisNeurosurgical review2026
Neurosurgical manifestations and management of mucopolysaccharidoses: A systematic review.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucopolysaccharidoses (MPS) represent a group of rare inherited lysosomal storage disorders, of which neurosurgical issues arise during childhood and adolescence. The literature however remains fragmented in terms of these specific outcomes. Correspondingly, we sought to synthesize a primer for neurosurgeons in regard to MPS, summarizing the neurosurgical manifestations and management reported in the contemporary literature. A systematic interrogation of the literature was performed according to PRISMA guidelines. Electronic databases were searched from inception through June 2026. Studies reporting hydrocephalus, craniovertebral junction (CVJ) abnormalities, spinal cord compression, myelopathy, spinal deformity, neurosurgical interventions, or related outcomes in patients with any MPS subtype were included and their findings aggregated. Seventy-eight studies comprising 983 patients with 37.8% females and mean age of 12.4 years were included. MPS I (34%), MPS II (31%), and MPS IV (26%) represented the majority of reported subtypes. A total of 819 patients (83%) exhibited neurosurgical manifestations. Spinal deformity (29%) and hydrocephalus (28%) were the most frequently reported manifestations, followed by spinal cord compression/myelopathy (22%) and CVJ pathology (20%). Distinct subtype-specific patterns were observed: spinal deformity predominated in MPS I (24%), hydrocephalus in MPS II (20%), and CVJ instability/compression in MPS IV (12%). Overall, hydrocephalus was surgically treated in 74% of instances, whereas CVJ and spinal cord pathology were surgically treated in 41% and 23% of instances respectively. Patients in studies who were not treated by any prior systemic therapy reported higher rates of surgical intervention compared to those who had received treatment. Neurosurgical manifestations occur in over four-fifths of MPS patients and are clinically significant across all types of MPS. Hydrocephalus, CVJ instability, spinal cord compression, and progressive spinal deformity represent the major surgical morbidities. Early recognition, structured imaging surveillance, and timely neurosurgical intervention are essential components of MPS management.
Indexed as
Identifiers
42900375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.